Swiss start-up Akroswiss has announced that it raised “several million Swiss Franc” for development of the company’s midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include Linsi, Bernhard Schuknecht, and Walter P. Hölzle, who is also the company’s Head of Business Development. According to the company, the single-use nasal spray is “a unique Bi-dose nasal drug delivery device for midazolam with a first-class 360° functionality.”
Schuknecht commented, “In our radiology institute, midazolam based nasal spray has been applied for many years during diagnostic examinations. The spray enables adequate resolution of anxiety and sedation and therefore, facilitates patients’ examinations. Akroswiss bi-dose spray is easy to administer and more hygienic than any other solution. Relief of anxiety by endonasal administration is a safe, effective route to improve patients’ comfort and image quality without the necessity of an intravenous line. An additional advantage of Akroswiss bi-dose nasal spray is the emergency endonasal administration of midazolam in patients with a sudden onset seizure. Thus, a safe route of endonasal administration on an emergency basis may effectively prevent potential harmful injuries and progression into a potential life-threatening seizure status.”
Schuknecht added, “To make this product available for more patients in need, a European marketing authorization is required. I believe Akroswiss and its team are best positioned to reach this within reasonable time.”
Read the Akroswiss press release.
